All 14 patients with advanced pancreatic cancer who were enrolled in a phase I clinical trial (NCT00729664) showed no responses to treatment with BMS-936559 (an anti-PD-L1 antibody)[180][Table 1]. Here, CD274 is linked to pancreatic neoplasm.